Evidence map›Paper›PMID 37410302›Full record

ArticleFunctional & integrative genomics2023

Comprehensive multiomics and in silico approach uncovers prognostic, immunological, and therapeutic roles of ANLN in lung adenocarcinoma.

Prithvi Singh, Shweta Arora, Md Amjad Beg, Sibasis Sahoo, Arnab Nayek, Mohd Mabood Khan, Anuradha Sinha, Md Zubbair Malik, Fareeda Athar, Mohammad Serajuddin and 2 more

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Functional & integrative genomics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Prithvi Singh *Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, New Delhi, 110025, India.
Shweta Arora *Translational Research Lab, Department of Biotechnology, Faculty of Natural Sciences, Jamia Millia Islamia, New Delhi, 110025, India.
Md Amjad BegCentre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, New Delhi, 110025, India.
Sibasis SahooMembrane Protein Biology Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, 110067, India.
Arnab NayekDepartment of Biochemistry, All India Institute of Medical Sciences, New Delhi, 110029, India.
Mohd Mabood KhanDepartment of Zoology, University of Lucknow, Lucknow, Uttar Pradesh, 226007, India.
Anuradha SinhaDepartment of Preventive Oncology, Homi Bhabha Cancer Hospital and Research Centre, Muzaffarpur, 842004, India.
Md Zubbair MalikDepartment of Genetics and Bioinformatics, Dasman Diabetes Institute, 15462, Dasman, Kuwait City, Kuwait.
Fareeda AtharCentre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, New Delhi, 110025, India.
Mohammad SerajuddinDepartment of Zoology, University of Lucknow, Lucknow, Uttar Pradesh, 226007, India.
Ravins DohareCentre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, New Delhi, 110025, India. ravinsdohare@gmail.com.
Mansoor Ali SyedTranslational Research Lab, Department of Biotechnology, Faculty of Natural Sciences, Jamia Millia Islamia, New Delhi, 110025, India. smansoor@jmi.ac.in.
Jamia Millia Islamia · INUniversity of Lucknow · INAll India Institute of Medical Sciences · INDasman Diabetes Institute · KWInternational Centre for Genetic Engineering and Biotechnology · IN

Funding

Indian Council of Medical Research 5/30/59/2020/NCD3
6 · The paper itself

Abstract

The anillin actin-binding protein (ANLN) is immensely overexpressed in cancers, including lung cancer (LC). Phytocompounds have gained interest due to their broader potential and reduced unwanted effects. Screening numerous compounds presents a challenge, but in silico molecular docking is pragmatic. The present study aims to identify the role of ANLN in lung adenocarcinoma (LUAD), along with identification and interaction analysis of anticancer and ANLN inhibitory phytocompounds followed by molecular dynamics (MD) simulation. Using a systematic approach, we found that ANLN is significantly overexpressed in LUAD and mutated with a frequency of 3.73%. It is linked with advanced stages, clinicopathological parameters, worsening of relapse-free survival (RFS), and overall survival (OS), pinpointing its oncogenic and prognostic potential. High-throughput screening and molecular docking of phytocompounds revealed that kaempferol (flavonoid aglycone) interacts strongly with the active site of ANLN protein via hydrogen bonds, Vander Waals interactions, and acts as a potent inhibitor. Furthermore, we discovered that ANLN expression was found to be significantly higher (p) in LC cells compared to normal cells. This is a propitious and first study to demonstrate ANLN and kaempferol interactions, which might eventually lead to removal of rout from cell cycle regulation posed by ANLN overexpression and allow it to resume normal processes of proliferation. Overall, this approach suggested a plausible biomarker role of ANLN and the combination of molecular docking subsequently led to the identification of contemporary phytocompounds, bearing symbolic anticancer effects. The findings would be advantageous for pharmaceutics but require validation using in vitro and in vivo methods. HIGHLIGHTS: • ANLN is significantly overexpressed in LUAD. • ANLN is implicated in the infiltration of TAMs and altering plasticity of TME. • Kaempferol (potential ANLN inhibitor) shows important interactions with ANLN which could remove the alterations in cell cycle regulation, imposed by ANLN overexpression eventually leading to normal process of cell proliferation.

Indexed as

Adenocarcinoma of LungLung NeoplasmsHumansKaempferolsMicrofilament ProteinsMolecular Docking SimulationMultiomicsPrognosisKaempferolsMicrofilament ProteinsANLNKaempferolLUADPrognosisTME

Identifiers

PMID37410302
OpenAlexW4383301750

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.